Company Overview - Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has been performing well in sales with its FDA-approved drug Rezdiffra (resmetirom), which is indicated for the treatment of adults with non-cirrhotic non-alcoholic fatty liver disease [2] Market Analysis - The Biotech Analysis Central service offers a comprehensive analysis of over 600 biotech investing articles and a model portfolio featuring more than 10 small and mid-cap stocks, providing in-depth analysis and live chat for healthcare investors [2]